LQDA

Liquidia develops inhaled therapies using its proprietary PRINT technology platform that creates precisely engineered drug particles for pulmonary and systemic delivery. The company's lead asset YUTREPIA won FDA approval in June 2024 as the first and only inhaled treprostinil for pulmonary arterial hypertension, entering a market dominated by expensive infusion pumps that patients desperately want to avoid. Commercial launch ramped through Q3 2024 with over 200 patients initiated on therapy and partnerships with major specialty pharmacies already in place. Trading at 7x forward earnings while sitting on a potential blockbuster that could capture meaningful share of the $2.8 billion PAH market, plus a deep pipeline applying PRINT technology to oncology and other respiratory diseases.